Last reviewed · How we verify
Glucose 33%
At a glance
| Generic name | Glucose 33% |
|---|---|
| Sponsor | Medical University of Vienna |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Prevention and Treatment of Common Hyperglycemia in Surgery Pilot (PHASE4)
- Comparison of Prolotherapy and Rehabilitation Treatments in Low Back Pain (CPRTLBP) (NA)
- Personalized Care for Prenatal Stress Reduction & Prevention of Preterm Birth (PTB) Disparities (NA)
- The Project for Managing Cardiometabolic Risk in Women Diagnosed With Gestational Diabetes Mellitus (NA)
- Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal Cancer (PHASE1)
- Technology Knowledge Optimization in Type 1 Diabetes (TeKnO T1D): Parents (NA)
- Breaking up Prolonged Sedentary Behavior to Improve Cardiometabolic Health (NA)
- Effect of Soliqua 100/33 on Time in Range From Continuous Glucose Monitoring in Insulin-naive Patients With Very Uncontrolled Type 2 Diabetes Mellitus (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Glucose 33% CI brief — competitive landscape report
- Glucose 33% updates RSS · CI watch RSS
- Medical University of Vienna portfolio CI